Inactive Instrument

Press Releases Oncolytics Biotech Inc. Toronto S.E.

Equities

CA6823101077

Press Releases

Unlock all the news: Be the first to know and act before the market!

Oncolytics Biotech Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program	06-28	AQ
Oncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer	06-20	PR
Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action	05-24	AQ
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders	05-16	PR
Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial	05-15	PR
Oncolytics Biotech Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer	05-10	AQ
Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights	05-09	AQ
Oncolytics Biotech® to Participate in a Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference	05-08	PR
Oncolytics Biotech to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights	05-01	AQ
Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights	04-30	AQ
Oncolytics Biotech Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting	04-26	AQ
Oncolytics Biotech® Announces Upcoming Presentations at the American Society of Clinical Oncology Annual Meeting	04-25	AQ
Oncolytics Biotech : NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 15, 2024 MANAGEMENT INFORMATION CIRCULAR - Form 6-K	04-12	PU
Oncolytics Biotech Advances toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA	04-12	AQ
Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA	04-11	PR
Oncolytics Biotech to participate in a Panel Presentation at Canaccord Genuity s Horizons in Oncology Virtual Conference	04-03	AQ
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning	03-06	NE
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights	03-04	AQ
Oncolytics Biotech Announces Presentation at the Cancer Advocacy Group of Louisiana's 3rd Annual NeauxCancer Conference	02-29	AQ
Cancer Immunotherapy Stocks - Tapping into Immune Systems for Next Generation Treatments	02-15	NE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Oncolytics Biotech Inc. Toronto S.E.

Equities

CA6823101077

Press Releases

Filters